Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

Mesalazine-Mesalamine-5-aminosalicylic acid-5-ASA

Mesalazine, mesalasine or 5-aminosalicylate. Several patterns or respiratory involvement caused by this drug can also be observed in the course of untreated inflammatory bowel disease UC and CD. Causality in cases with exposure to mesalazine and anti-TNF agents can be difficult to disentangle (PMID: 23983443). Drug-induced involvement in IBD is against the specific respiratory and cardiovasculare manifestations of the IBD UC and CD (PMID: 22958334)

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (interstitial lung disease/ILD)
I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d

Acute eosinophilic pneumonia (AEP)
I.e

Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.n

ILD with a granulomatous component
I.aa

An area or areas of consolidation

XLI - Pulmonary edema - Acute lung injury - ARDS

XLI.b

Pulmonary edema, cardiogenic

XLIII - Airway involvement

XLIII.j

Bronchiectasis
XLIII.l

Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)
XLIII.w

Bronchiolitis (a clinical-imaging pattern suggestive of)
XLIII.x

Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

XLIV - Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.ax

Tracheitis including eosinophilic tracheal inflammation

XLV - Pleural and/or pericardial involvement

XLV.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
XLV.b

Eosinophilic pleural effusion
XLV.m

Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLIX - Systemic/Distant conditions, syndromes and reactions

XLIX.a

DRES syndrome - DRESS-like reaction
XLIX.d

Lupus - Lupus syndrome (see also Vd)

L - Miscellaneous

L.b

Chest pain (acute or subacute), lone or prominent

LI - Cardiovascular involvement / toxicity

LI.a

Left or biventricular dysfunction/failure
LI.c

Pericardial effusion (w/wo tamponade)
LI.d

Myocarditis (can be fulminant)
LI.h

Coronary artery disease (acute) - Myocardial ischemia/infarction
LI.i

Eosinophilic myocarditis
LI.o

Cardiovascular collapse - Cardiogenic shock - Hypotension
LI.r

Pericarditis (see also under XIIc)
LI.bi

Myopericarditis (see under XIIc/d/g)

LV - Imaging

LV.b

Imaging: Ground-glass opacities (GGO) / shadowing
LV.k

Imaging: An area or areas of consolidation
LV.ba

Imaging: Asymmetrical, predominantly unilateral involvement

LVII - Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a

BAL: An excess proportion of lymphocytes
LVII.c

BAL: An excess proportion of eosinophils

LVIII - Pathology

LVIII.a

Path: NSIP-cellular pattern (see also Ia, Ib)
LVIII.b

Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
LVIII.d

Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
LVIII.f

Path: ILD with a granulomatous component (see also Im)
LVIII.aq

Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)